Clinical Trials
9
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:2
Phase 3:1
Not Applicable:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Not Applicable
6 (66.7%)Phase 1
2 (22.2%)Phase 3
1 (11.1%)A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Phase 3
Recruiting
- Conditions
- Glioblastoma MultiformeGliomaBrain Tumor, RecurrentNeoplasms, Nerve TissueBrain TumorNeoplasmsGlioblastomaGlioblastoma Multiforme, Adult
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 32
- Registration Number
- NCT06496971
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
Not Applicable
Recruiting
- Conditions
- EpilepsyDrug Resistant EpilepsyEpilepsy, Temporal Lobe
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT06492720
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
Phase 1
Recruiting
- Conditions
- Drug Resistant EpilepsyEpilepsy
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT06388707
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Virginia School of Medicine, Charlottesville, Virginia, United States
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Phase 1
Not yet recruiting
- Conditions
- Glioblastoma MultiformeGliomaBrain TumorNeoplasmsGlioblastomaNeoplasms, Nerve Tissue
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT06329570
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
Not Applicable
Recruiting
- Conditions
- Drug Resistant Epilepsy
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- NaviFUS Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT04999046
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
- Prev
- 1
- 2
- Next
News
No news found